Analysis of Risk Factors for Hepatocellular Carcinoma Caused by Hepatitis

Authors

  • Bowen Zheng

DOI:

https://doi.org/10.61173/d960zt97

Keywords:

HBV, HCV, HCC, NASH

Abstract

Liver cancer is a malignant tumor, of which hepatocellular carcinoma (HCC) is the most common type, accounting for approximately 90% of liver cancer cases. HCC ranks sixth in cancer incidence and third in cancer mortality, causing significant impact on patients and society. HCC usually occurs in the setting of chronic liver disease and cirrhosis but can also occur in individuals without underlying liver disease. Therefore, understanding the risk factors of HCC can effectively help patients with treatment. The occurrence of HCC is closely related to many factors, among which hepatitis B and hepatitis C play a major role. This article mainly analyzes three risk factors: HBV, HCV, and non-alcoholic steatohepatitis (NASH). A comprehensive analysis of the intrinsic mechanisms of HCC caused by these three factors provides a reference for future treatment and diagnosis. Although the infection rates of HBV and HCV are declining significantly, their underlying factors cannot be ignored. In the future, research can focus more on exploring more risk factors.

References

[1] Guo, M., Jiang, C., Songyang, Z., Xiong, Y., et al. Multiomics analyses reveal pathological mechanisms of HBV infection and integration in liver cancer. Journal of Medical Virology, 2023, (8).

[2] Panneerselvam S, Wilson C, Kumar P, et al. Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options. Cell Adhesion & Migration, 2023, 17(1): 1-21.

[3] Chen-hao Zhang, Yifei Cheng, et al. Changing epidemiology of hepatocellular carcinoma in Asia. Liver International, 2022,42(9), 2029–2041.

[4] Dash, S., Aydin, Y., Widmer, K. E., & Nayak, L. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. Journal of Hepatocellular Carcinoma, 2020,7, 45–76.

[5] Mohamad B, Shah V, Onyshchenko M, et al. Characterization of HCC in non-alcoholic fatty liver disease NAFLD) patients without cirrhosis. Hepatol Int 2016;10(4):632–9.

[6] Shen, C., Jiang, X., Li, M., & Luo, Y. Hepatitis Virus and Hepatocellular Carcinoma: Recent Advances. Cancers, 2023, (2), 533.

[7] Patel, S. In silico analysis of Hepatitis C virus (HCV) polyprotein domains and their comparison with other pathogens and allergens to gain insight on pathogenicity mechanisms. Computational Biology and Chemistry, 2016, 91–102.

[8] Fabrizi, F., Cerutti, R., Dixit, V., & Messa, P. The impact of antiviral therapy for HCV on kidney disease: a systematic review and meta-analysis. Nefrología (English Edition), 2020,

[9] Lujambio, A., & Sarobe, P. Metformin keeps CD8 + T cells active and moving in NASH-HCC immunotherapy. Journal of Hepatology, 2022, (3), 593–595.

[10] Huang, D. Q., Singal, A. G., Kono, Y., et al. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest-growing cause of liver cancer. Cell Metabolism, 2022.

Downloads

Published

2024-06-06